查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2022-2029 年連續血糖監測的全球市場
市場調查報告書
商品編碼
776946

2022-2029 年連續血糖監測的全球市場

Global Continuous Glucose Monitoring Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

全球持續血糖監測市場的增長是由對預防性糖尿病護理、新產品發布和政府支持措施的認識不斷提高推動的。開發新穎且技術先進的 CGM 已成為血糖監測設備製造商的主要關注點。它為所有年齡段和醫療保健環境提供了廣泛的應用。

連續血糖監測 (CGM) 設備的日益普及將推動市場增長

對於依賴胰島素泵或每日註射胰島素的患者，連續血糖監測 (CGM) 是一種有用的工具，可在不增加致命低血糖風險的情況下增強血糖平衡。建立自己。多項臨床試驗表明，1 型糖尿病（T1DM）患者在使用持續血糖監測時的血糖控制優於每日使用血糖儀自我監測血糖。這種趨勢在兒童和定期使用連續血糖監測 (CGM) 的患者中是相似的。這些兒童的結果顯示出更好的糖化血紅蛋白 (HbA1c) 水平，而沒有增加低血糖發生率。

目前已獲批准的連續血糖監測 (CGM) 模型使用基於葡萄糖氧化□的電化學皮下傳感器來檢測間質液中的葡萄糖水平。連續血糖監測 (CGM) 設備包括通過下載數據回顧顯示血糖趨勢，以及提供實時血糖水平的接收器顯示器。大多數實時連續血糖監測 (CGM) 設備可以在實際或待定血糖訪問期間提醒患者、父母或護理人員，以便及時控制血糖水平。我可以做到。然而，連續血糖監測 (CGM) 設備缺乏準確性、需要頻繁校準以及醫療保險報銷的不一致是製約市場增長的主要因素。

缺乏適當的設備報銷阻礙了市場增長

但是，缺乏足夠的設備報銷仍然是設備採用的主要障礙。這種缺乏報銷的可能是由於該設備被 FDA 批准為標準家用血糖儀的輔助療法。在美國等地進行報銷時，只有特定的患者群體才能獲得符合嚴格適應症的報銷。鑑於臨床試驗已證明使用 CGM 是有益的，這種情況有些令人驚訝。

COVID-19 影響分析

在 COVID-19 大流行期間，隨著聯邦機構放寬限制並發佈在醫院環境中使用家用血糖儀或 CGM 的指南，對連續血糖監測設備的需求正在增加Nicole Ehrhardt 等人於 2020 年 11 月在糖尿病護理雜誌上發表的一項研究發現，COVID-19 大流行需要在醫院持續監測血糖，以保存個人防護設備 (PPE) 並限制醫護人員的接觸。評估監測（CGM）可行性的新需求。此外，7.8–10.0 mmol/L (140–180 mg/dL) 的血糖控制在許多醫院對 ICU 和非 ICU 區域的 COVID-19 感染者來說是一個挑戰。

根據 Sandip Garg 等人的一項研究，據說它承受著相當大的財務壓力。糖尿病護理是大流行和技術在改變醫療保健提供方面日益重要的融合的一個例子。在大流行期間，COVID-19 給美國帶來的直接醫療保健成本估計在 1600 億美元（感染人口的 20%）和 6500 億美元（感染人口的 80%）之間。 COVID-19 的流行凸顯了糖尿病患者對良好血糖控制的需求。這是因為大多數觀察性研究報告說，糖尿病控制不佳與因病毒性疾病而住院和死亡的風險增加有關。

本研究報告將提供對全球連續血糖監測市場大約 40 多個市場數據表、45 多個數字和 200 多頁（大約）的訪問權限。

內容

第 1 章全球連續血糖監測市場研究方法和範圍

  • 調查方法
  • 調查目的和範圍

第 2 章全球連續血糖監測市場 - 市場定義和概述

第 3 章全球連續血糖監測市場-執行摘要

  • 按組件劃分的市場細分
  • 最終用戶的市場細分
  • 按地區劃分的市場細分

第 4 章全球連續血糖監測市場 - 市場動態

  • 市場影響因子
    • 驅動程序
      • 越來越多地採用連續血糖監測 (CGM) 設備
      • 糖尿病患者增加
    • 約束因素
      • 醫療保險報銷不一致
    • 商機
    • 影響分析

第 5 章全球連續血糖監測市場-行業分析

  • 波特五力分析
  • 供應鏈分析
  • 監管分析

第 6 章全球持續血糖監測市場 - COVID-19 分析

  • 對 COVID-19 市場的分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章全球連續血糖監測市場 - 按組件

  • 發射器
  • 接收者
  • 傳感器
  • 胰島素泵
  • 其他

第 8 章全球持續血糖監測市場 - 按最終用戶分類

  • 診斷中心
  • 重症監護室
  • 家庭保健

第 9 章全球連續血糖監測市場 - 按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 10 章全球連續血糖監測市場 - 競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 產品基準

第 11 章全球連續血糖監測市場 - 公司簡介

  • Abbott Laboratories
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Dexcom, Inc.
  • A. Menarini Diagnostics s.r.l
  • Echo Therapeutics, Inc.
  • GlySens Incorporated
  • Johnson and Johnson
  • Medtronic Plc
  • Senseonics Holdings, Inc.
  • F. Hoffmann-La Roche Ltd
  • Medtrum Technologies, Inc.

第 12 章全球連續血糖監測市場 - DataM

簡介目錄
Product Code: DMMD699

Market Overview

The Global "Continuous Glucose Monitoring Market" is expected to grow at a high CAGR of 22.0% during the forecast period (2022-2029).

Continuous Glucose Monitoring (CGM) devices are the advancement in diabetes management, where the blood glucose is under continuous monitor. The introduction of CGM devices integrated with insulin pumps using transmitters, receivers, and glucose sensors also increased their adoption due to improved convenience. The process of data collection through CGM has helped people keep track of their daily glucose levels.

Market Dynamics

The global continuous glucose monitoring market growth is driven by the growing awareness about diabetes preventive care, new product launches, and supportive government initiatives. The development of novel and technologically advanced CGM is the prime focus of glucose monitoring device manufacturing companies. It offers a wide range of applications for all age-cohorts, healthcare settings.

Increasing adoption of continuous glucose monitoring (CGM) devices will drive the market growth

The patients reliant on insulin pumps or daily insulin injections, continuous glucose monitoring (CGM) establishes itself to be an instrumental tool, which helps in the enhancement of glycemic balance without increasing the danger of fatal hypoglycemia. As studied in several clinical trials, diabetic patients with Type 1 diabetes mellitus (T1DM) using continuous glucose monitoring have shown to have better glycemic control, in comparison to when glucometer is used for routine self-monitoring blood glucose. The trend follows in children, as well as those who use continuous glucose monitoring (CGM) on a regular basis. The results in these children show better-glycosylated hemoglobin (HbA1c) levels without an amplified frequency of hypoglycemia.

The current continuous glucose monitoring (CGM) models approved administer glucose oxidase-based electrochemical subcutaneous sensors for the detection of glucose levels in the interstitial fluid. Continuous glucose monitoring (CGM) devices can either retrospectively display the trends in the levels of blood glucose by downloading the data or give a real-time picture of glucose levels through receiver displays. Most of the real-time continuous glucose monitoring (CGM) devices can offer an alert to patients, parents, or caregivers during actual or pending glycemic visits, to facilitate timely management of blood glucose. However, lack of accuracy of continuous glucose monitoring (CGM) devices, need for frequent calibration, and inconsistency of medicare reimbursement are the major factors restraining the market growth.

Lack of adequate reimbursement for devices will hamper the market growth

However, lack of adequate reimbursement for devices is the key barrier to the adoption of the devices. This lack of coverage is likely due to the devices receiving FDA approval as adjunctive therapy to standard home blood glucose monitors. In case reimbursement is in a place like in the United States, only certain patient groups get the reimbursement that fulfills strict indications. This situation is somewhat surprising in view of the mounting evidence for benefits of CGM usage from clinical trials.

COVID-19 Impact Analysis

Increased demand for continuous glucose monitoring devices amid the COVID-19 pandemic is attributed to the loosened restricted regulations and issued guidelines for the use of home-use glucose meters or CGMs in hospital settings by the federal agencies. According to the research study by Nicole Ehrhardt et al., published in Diabetes Care Journal November 2020, the COVID-19 pandemic has brought a new urgency to the need to assess the feasibility of continuous glucose monitoring (CGM) in the hospital to preserve personal protective equipment (PPE) and limit health care worker's exposure. Moreover, glycemic control of 7.8-10.0 mmol/L (140-180 mg/dL) is a challenge for many hospitals in both the ICU and non-ICU areas for those infected with COVID-19.

According to a research study by Sandip Garg et al., published in Diabetes Technology & Therapeutics Journal March 2021, the COVID-19 pandemic has exposed vulnerabilities and placed tremendous financial pressure on nearly all aspects of the United States health care system. Diabetes care is an example of the confluence of the pandemic and heightened importance of technology in changing care delivery. It has been estimated the added total direct United States medical cost burden due to COVID-19 to range between USD 160B (20% of the population infected) and USD 650B (80% of the population infected) over the course of the pandemic. The COVID-19 pandemic emphasizes the need for good glycemic control in patients with diabetes, in large part because most observational studies have reported poorly controlled diabetes is associated with a higher risk for hospitalization and death from a viral illness.

Segment Analysis

The sensor segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

Continuous glucose monitoring sensors use glucose oxidase to detect blood sugar levels. Glucose oxidase converts glucose to hydrogen peroxidase, which reacts with the platinum inside the sensor, producing an electrical signal to be communicated into the transmitter. Sensors are the most important part of continuous glucose monitoring devices. Technological advancements to improve the accuracy of the sensors are expected to drive segment growth during the forecast period. Globally, diabetes mellitus has been of wide concern with its high global prevalence, resulting in increased financial burdens for clinical systems, individuals, and governments. Continuous glucose monitoring has become a popular alternative to the portable finger-prick glucometers available in the market for the convenience of diabetic patients. According to a research study by Ziyi Yu et al., published in IOP Science Journal March 2021, a large variety of promising glucose-sensing technologies from traditional electrochemical-based glucose sensors to novel optical and other electrical glucose sensors has been developed which shows a positive impact on the market growth.

Geographical Analysis

North America region holds the largest market share of the global continuous glucose monitoring market

North America has the largest market share in the forecast period. Some of the factors that are driving the market growth in the North American region include increasing cases of diabetes and efforts taken by the national government to manage the disease at a larger level along with rising adoption of alternate and novel devices and the presence of key market players. In April 2020, Abbott Laboratories and Dexcom, Inc. received United States Food and Drug Administration (FDA) approval to use continuous glucose monitoring in United States hospitals for Coronavirus-affected people. Dexcom began shipping continuous glucose monitoring devices to hospitals in April 2020 and plans to make 100,000 sensors to sell to hospitals at a low cost and planned to donate 10,000 phones and continuous glucose monitoring readers to hospitals for scanning those sensors.

As per Diabetes Canada, in 2020, there were around 11 million Canadians with diabetes or prediabetes. As the trends show a higher number of diabetic patients using insulin pumps for diabetes management, it can be predicted that the number of units of continuous glucose monitoring devices sold will also follow. Thus, owing to the above factors it is expected to drive the market growth over the forecast period.

Competitive Landscape

The continuous glucose monitoring market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Abbott Laboratories, Dexcom, Inc., A. Menarini Diagnostics s.r.l, Echo Therapeutics, Inc., GlySens Incorporated, Johnson and Johnson, Medtronic Plc, Senseonics Holdings, Inc., F. Hoffmann-La Roche Ltd, Medtrum Technologies, Inc. among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the continuous glucose monitoring market globally. For instance, in June 2020, Menarini Diagnostics has launched GlucoMen Day CGM, an innovative digital patch, wearable for fourteen days in a row, which monitors blood glucose and shows results directly on the smartphone.

Abbott Laboratories

Overview:

Abbott Laboratories is a U.S. health care company. The Company operates through four segments: established pharmaceutical products, diagnostic products, nutritional products, and medical devices.

Product Portfolio:

FreeStyle Libre 2: FreeStyle Libre 2 is a sensor-based glucose monitoring system that comes with a reader and a sensor. The sensor is applied to the back of the upper arm and can be worn for up to 14 days.

Why Purchase the Report?

Visualize the composition of the global continuous glucose monitoring market segmentation by component, end-user, and region highlighting the key commercial assets and players.

Identify commercial opportunities in the global continuous glucose monitoring market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global continuous glucose monitoring market-level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global continuous glucose monitoring market report would provide access to an approximately 40+ market data table, 45+ figures, and in the range of 200 (approximate) pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Market Segmentation

Global Continuous Glucose Monitoring Market- By Component

Transmitter

Receiver

Sensor

Insulin pumps

Others

Global Continuous Glucose Monitoring Market- By End User

Diagnostics Centers

ICUs

Home Healthcare

Global Continuous Glucose Monitoring Market- By Region

North America

Europe

Asia-Pacific

Middle East & Africa

South America

Table of Contents

1. Global Continuous Glucose Monitoring Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Continuous Glucose Monitoring Market-Market Definition and Overview

3. Global Continuous Glucose Monitoring Market- Executive Summary

  • 3.1. Market Snippet By Component
  • 3.2. Market Snippet By End User
  • 3.3. Market Snippet by Region

4. Global Continuous Glucose Monitoring Market-Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Adoption of Continuous Glucose Monitoring (CGM) Devices
      • 4.1.1.2. Growing Cases of Diabetes
    • 4.1.2. Restraints:
      • 4.1.2.1. Inconsistency of Medicare Reimbursement
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Continuous Glucose Monitoring Market- Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. Global Continuous Glucose Monitoring Market- COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Continuous Glucose Monitoring Market- By Component

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Component Segment
    • 7.1.2. Market Attractiveness Index, By Component Segment
  • 7.2. Transmitter*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Receiver
  • 7.4. Sensor
  • 7.5. Insulin pumps
  • 7.6. Others

8. Global Continuous Glucose Monitoring Market- By End User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 8.1.2. Market Attractiveness Index, By End User Segment
  • 8.2. Diagnostics Centers*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. ICUs
  • 8.4. Home Healthcare

9. Global Continuous Glucose Monitoring Market- By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Component
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. The U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Component
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Component
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Component
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Component
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

10. Global Continuous Glucose Monitoring Market- Competitive Landscape

  • 10.1. Key Developments and Strategies
  • 10.2. Company Share Analysis
  • 10.3. Product Benchmarking

11. Global Continuous Glucose Monitoring Market- Company Profiles

  • 11.1. Abbott Laboratories*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Dexcom, Inc.
  • 11.3. A. Menarini Diagnostics s.r.l
  • 11.4. Echo Therapeutics, Inc.
  • 11.5. GlySens Incorporated
  • 11.6. Johnson and Johnson
  • 11.7. Medtronic Plc
  • 11.8. Senseonics Holdings, Inc.
  • 11.9. F. Hoffmann-La Roche Ltd
  • 11.10. Medtrum Technologies, Inc.

LIST NOT EXHAUSTIVE

12. Global Continuous Glucose Monitoring Market - DataM

  • 12.1. Appendix
  • 12.2. About Us and Services
  • 12.3. Contact Us